HC Wainwright reissued their buy rating on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Thursday morning. HC Wainwright currently has a $3.00 target price on the biotechnology company’s stock.

“Our new price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc.”,” HC Wainwright’s analyst commented.

A number of other brokerages have also recently commented on BLPH. Zacks Investment Research cut Bellerophon Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 11th. ValuEngine raised Bellerophon Therapeutics from a hold rating to a buy rating in a research note on Friday, June 8th.

Bellerophon Therapeutics traded down $0.03, reaching $0.63, during mid-day trading on Thursday, MarketBeat.com reports. The stock had a trading volume of 754,428 shares, compared to its average volume of 1,045,595. Bellerophon Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $3.30.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter. research analysts predict that Bellerophon Therapeutics will post -0.4 EPS for the current year.

A number of institutional investors have recently made changes to their positions in BLPH. Bank of New York Mellon Corp acquired a new stake in Bellerophon Therapeutics in the fourth quarter valued at approximately $458,000. Renaissance Technologies LLC grew its stake in Bellerophon Therapeutics by 25.3% in the fourth quarter. Renaissance Technologies LLC now owns 927,200 shares of the biotechnology company’s stock valued at $2,392,000 after acquiring an additional 187,200 shares during the period. Finally, DRW Securities LLC acquired a new stake in Bellerophon Therapeutics in the first quarter valued at approximately $146,000. 57.99% of the stock is owned by hedge funds and other institutional investors.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Further Reading: Leveraged Buyout (LBO) Explained

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.